Cargando…
Empagliflozin Ameliorates Type 2 Diabetes-Induced Ultrastructural Remodeling of the Neurovascular Unit and Neuroglia in the Female db/db Mouse
Type 2 diabetes is associated with diabetic cognopathy. Anti-hyperglycemic sodium glucose transporter 2 (SGLT2) inhibitors have shown promise in reducing cognitive impairment in mice with type 2 diabetes mellitus. We recently described marked ultrastructural (US) remodeling of the neurovascular unit...
Autores principales: | Hayden, Melvin R., Grant, DeAna G., Aroor, Annayya R., DeMarco, Vincent G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468773/ https://www.ncbi.nlm.nih.gov/pubmed/30866531 http://dx.doi.org/10.3390/brainsci9030057 |
Ejemplares similares
-
Cardioprotective effects of short-term empagliflozin treatment in db/db mice
por: Radlinger, Bernhard, et al.
Publicado: (2020) -
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
por: Habibi, Javad, et al.
Publicado: (2017) -
Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice
por: Klimontov, Vadim V, et al.
Publicado: (2020) -
Ultrastructural Remodeling of the Blood–Brain Barrier and Neurovascular Unit by Lipopolysaccharide-Induced Neuroinflammation
por: Erickson, Michelle A., et al.
Publicado: (2023) -
Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice
por: Tu, Yimin, et al.
Publicado: (2022)